search
Back to results

Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device

Primary Purpose

Laryngopharyngeal Reflux

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Reza Band UES Assist Device
Sponsored by
Somna Therapeutics, L.L.C.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Laryngopharyngeal Reflux

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18 year of age or older
  • The patient must be willing and able to provide informed consent.
  • Understands the clinical study requirements and is able to comply with follow-up schedule.
  • Clinically diagnosed with esophagopharyngeal reflux with extra-esophageal symptoms (i.e., chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing)
  • Reflux Symptom Index (RSI) >13

Exclusion Criteria:

  • Currently being treated with another investigational medical device and/or drug
  • Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP)
  • The patient is female and is of child bearing potential and is not using an acceptable method of birth control, or is pregnant or breast feeding.
  • Previous head or neck surgery or radiation
  • Carotid artery disease, thyroid disease, or history of cerebral vascular disease
  • Suspected esophageal cancer
  • Has either a pacemaker or implanted cardioverter defibrillator (ICD)
  • Nasopharyngeal cancer
  • Previously undergone Nissen Fundoplication

Sites / Locations

  • Dr. Alan Raymond
  • Madison ENT & Facial Plastic surgery
  • Vanderbilt University
  • Wisconsin Center for Advanced Research
  • Aurora Health Care

Arms of the Study

Arm 1

Arm Type

Active Comparator

Arm Label

Reza Band UES Assist Device

Arm Description

Patient is own control. Compare baseline to last follow-up after using device

Outcomes

Primary Outcome Measures

Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks
The RSI is a validated nine-item patient-administered outcome questionnaire designed to document symptoms and severity. Patients are asked to rate how nine problems have affected them on a scale of 0 (no problem) to 5 (severe problem), with a maximum total score of 45).
Primary Safety
Adverse reactions reported were evaluated with the frequency and percent of subjects of each reaction being summarized by severity and by relationship to the Reza Band UES Assist Device.

Secondary Outcome Measures

SF-36 Short Form Health Survey - 4 Week Follow-up Score Compared to Baseline Score
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Functional Outcomes of Sleep Questionnaire (FOSQ)
The FOSQ is a self-report measure (0-4 for each of 30 questions) designed to assess the impact of disorders of excessive sleepiness (DOES) on multiple activities of everyday living that includes areas of physical, mental and social functioning. Scores can range from 0 (worst possible outcome) to 120 (best possible outcome). Zero (0) is defined as not doing that specific activity for other reasons.

Full Information

First Posted
May 16, 2013
Last Updated
May 20, 2015
Sponsor
Somna Therapeutics, L.L.C.
search

1. Study Identification

Unique Protocol Identification Number
NCT01857713
Brief Title
Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device
Official Title
A Multi-Center, Non-Randomized, Prospective Study of the Reza Band™ Upper Esophageal Sphincter (UES) Assist Device for the Treatment of Esophagopharyngeal Reflux
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Somna Therapeutics, L.L.C.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to determine the safety and effectiveness of non-invasive Reza Band UES Assist Device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing).
Detailed Description
The purpose of the study is to determine the safety and effectiveness of non-invasive Reza Band UES Assist Device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing). Reza Band is to be worn when sleeping. The patient will put the Reza Band on at bedtime and take it off upon waking. This is a prospective, non-randomized, open label, multicenter study designed to assess the safety and effectiveness of the Reza Band. At up to 5 investigational sites, up to 100 subjects will be enrolled. The primary effectiveness endpoint is to be evaluated by the Reflux Symptom Index (RSI). Success is defined as >25% reduction in the RSI at the last follow-up, as compared to the baseline RSI. The RSI is a validated nine-item patient-administered outcome questionnaire designed to document symptoms and severity. Patients are asked to rate how nine problems have affected them on a scale of 0 (no problem) to 5 (severe problem), with a maximum total score of 45. All adverse reactions being reported will be evaluated with the frequency and percent of subjects of each reaction being summarized by severity and by relationship to the Reza Band. Since some subjects may report the same event several times (e.g., redness), the first occurrence of the worst reported case of the event will be used for the purpose of analysis. The incidence of site reactions, including laryngospasm, choking, pain, cough and hoarseness will be summarized. Exact 95% confidence intervals for the incidence rate of site reactions will be presented.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Laryngopharyngeal Reflux

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
95 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Reza Band UES Assist Device
Arm Type
Active Comparator
Arm Description
Patient is own control. Compare baseline to last follow-up after using device
Intervention Type
Device
Intervention Name(s)
Reza Band UES Assist Device
Intervention Description
Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
Primary Outcome Measure Information:
Title
Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks
Description
The RSI is a validated nine-item patient-administered outcome questionnaire designed to document symptoms and severity. Patients are asked to rate how nine problems have affected them on a scale of 0 (no problem) to 5 (severe problem), with a maximum total score of 45).
Time Frame
4 Weeks minus Baseline
Title
Primary Safety
Description
Adverse reactions reported were evaluated with the frequency and percent of subjects of each reaction being summarized by severity and by relationship to the Reza Band UES Assist Device.
Time Frame
4 Week Follow-up
Secondary Outcome Measure Information:
Title
SF-36 Short Form Health Survey - 4 Week Follow-up Score Compared to Baseline Score
Description
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time Frame
4 Weeks minus Baseline
Title
Functional Outcomes of Sleep Questionnaire (FOSQ)
Description
The FOSQ is a self-report measure (0-4 for each of 30 questions) designed to assess the impact of disorders of excessive sleepiness (DOES) on multiple activities of everyday living that includes areas of physical, mental and social functioning. Scores can range from 0 (worst possible outcome) to 120 (best possible outcome). Zero (0) is defined as not doing that specific activity for other reasons.
Time Frame
4 Weeks minus Baseline
Other Pre-specified Outcome Measures:
Title
Patient Satisfaction
Description
Patients provide their perception of the device at the end of the study.
Time Frame
4 Weeks
Title
Investigator Questionnaire
Description
Investigators provide their perception of the device at the end of the study.
Time Frame
4 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18 year of age or older The patient must be willing and able to provide informed consent. Understands the clinical study requirements and is able to comply with follow-up schedule. Clinically diagnosed with esophagopharyngeal reflux with extra-esophageal symptoms (i.e., chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing) Reflux Symptom Index (RSI) >13 Exclusion Criteria: Currently being treated with another investigational medical device and/or drug Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP) The patient is female and is of child bearing potential and is not using an acceptable method of birth control, or is pregnant or breast feeding. Previous head or neck surgery or radiation Carotid artery disease, thyroid disease, or history of cerebral vascular disease Suspected esophageal cancer Has either a pacemaker or implanted cardioverter defibrillator (ICD) Nasopharyngeal cancer Previously undergone Nissen Fundoplication
Facility Information:
Facility Name
Dr. Alan Raymond
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Madison ENT & Facial Plastic surgery
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Vanderbilt University
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212
Country
United States
Facility Name
Wisconsin Center for Advanced Research
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Facility Name
Aurora Health Care
City
Summit
State/Province
Wisconsin
ZIP/Postal Code
50366
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device

We'll reach out to this number within 24 hrs